Profile_bird

Hey there! BioPharmaToday is using Twitter.

Twitter is a free service that lets you keep in touch with people through the exchange of quick, frequent answers to one simple question: What are you doing? Join today to start receiving BioPharmaToday's tweets.

Already using Twitter
from your phone? Click here.

BioPharmaToday

  1. GSK Coughs Up $40 M for Option on Nabi's Late-Stage Smoking Vaccine NicVAX http://bit.ly/3bRRtD
  2. Continuing Allston Troubles Mean Another Brief Shutdown, Delay For Lumizyme Approval http://bit.ly/7uoCw
  3. Bristol Flying Solo As A Pure Biopharma After Mead Johnson Spin Out http://bit.ly/2tApX6
  4. Xolair Pediatric (Ages 6-11) BLA Extension Must Overcome “Relatively Modest” Efficacy http://bit.ly/3a4hzK
  5. Special Medical Liaisons Are No Back Door To Off-Label Promotion – Experts http://bit.ly/3tb1fW
  6. Coming in Tuesday's "The Pink Sheet" DAILY http://bit.ly/33Z67O
  7. Looking For Creative Strategies To Optimize Your Drug's Positioning & Reimbursement? http://bit.ly/3O37zH
  8. Latest News From PharmAsia News http://bit.ly/3mrttV
  9. Latest News from "The Pink Sheet" DAILY http://bit.ly/FjGkh
  10. Editors' Picks from the World Press http://bit.ly/3BHIFq
  11. Eli Lilly Hires AstraZeneca's Jan Lundberg To Replace Steve Paul As Head Of R&D http://bit.ly/4vVDwM
  12. FDA’s Temple Changes Roles As Part Of CDER Shuffle http://bit.ly/3zrAob
  13. Genzyme, FDA Warn Of Foreign Particles Found In Some Lots Of Five Drugs http://bit.ly/25Zf52
  14. Possible Legislation Regarding ESA Administration On The Horizon http://bit.ly/2XBjVN
  15. FDA Is Expanding Transparency Efforts To Focus On Industry Questions http://bit.ly/3a6X1L
  16. China's Hutchison MediPharma Phase IIb Trials In Ulcerative Colitis Meet Primary, Secondary Endpoints http://bit.ly/2Wm5Bo
  17. Coming In Monday's "The Pink Sheet" DAILY http://bit.ly/1Qk14H
  18. Best Practices For Patient Registries Are Evolving - Are You Prepared? http://bit.ly/2I0oTF
  19. Latest News from "The Pink Sheet" DAILY http://bit.ly/16B4xl
  20. Editors' Picks from The World Press http://bit.ly/2QMTe2